GPBAR1 and cholangiocarcinoma: Similarly, TGR5 activation in CCA cells promotes tumor progression, its downregulation in cholangiocytes and tumor-associated macrophages attenuates inflammation through NF-κB and MAPK/ERK pathway inhibition (52, 122).